2716890-91-2

CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 μM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties[1].

CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 μM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties[1].

Store at -20°C

[1]. Prigaro BJ, et al. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022;65(5):3943-3961.